Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan W Partin

Showing results (71-80 of 349) with videos related to

Pageof 35
Sort By:
Urology|September 22, 2012
Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification systemAdam C Reese, Phillip M Pierorazio, Misop Han, et al.
Urology|February 25, 2017
Patterns of Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy for Low-risk MenHeather J Chalfin, Zhaoyong Feng, Bruce J Trock, et al.
The Journal of Urology|June 4, 2013
Adenocarcinoma of the prostate with Gleason score 9-10 on core biopsy: correlation with findings at radical prostatectomy and prognosisCarla L Ellis, Alan W Partin, Misop Han, et al.
The Prostate|December 29, 2006
Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic diseaseMichael W Shafer, Leslie Mangold, Alan W Partin, et al.
Annual Review of Medicine|October 25, 2008
Biomarkers for prostate cancerDanil V Makarov, Stacy Loeb, Robert H Getzenberg, et al.
BJU International|July 9, 2011
Effect of intra-observer variation in prostate volume measurement on prostate-specific antigen density calculations among prostate cancer active surveillance participantsJoan S Ko, Patricia Landis, H Ballentine Carter, et al.
The Journal of Urology|December 11, 2003
An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy seriesMisop Han, Alan W Partin, David Y Chan, et al.
Urology|January 30, 2004
Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancerGlenn M Cannon, Patrick C Walsh, Alan W Partin, et al.
The Journal of Applied Laboratory Medicine|February 27, 2021
High "phi"veLori J Sokoll, Leslie Mangold, Phaedre Mohr, et al.
Urology|October 18, 2002
Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancerRobert W Veltri, M Craig Miller, Gerard J O'dowd, et al.
Pageof 35

Showing results (71-80 of 349) with videos related to

Sort By:
Pageof 35
Urology|September 22, 2012
Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification systemAdam C Reese, Phillip M Pierorazio, Misop Han, et al.
Urology|February 25, 2017
Patterns of Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy for Low-risk MenHeather J Chalfin, Zhaoyong Feng, Bruce J Trock, et al.
The Journal of Urology|June 4, 2013
Adenocarcinoma of the prostate with Gleason score 9-10 on core biopsy: correlation with findings at radical prostatectomy and prognosisCarla L Ellis, Alan W Partin, Misop Han, et al.
The Prostate|December 29, 2006
Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic diseaseMichael W Shafer, Leslie Mangold, Alan W Partin, et al.
Annual Review of Medicine|October 25, 2008
Biomarkers for prostate cancerDanil V Makarov, Stacy Loeb, Robert H Getzenberg, et al.
BJU International|July 9, 2011
Effect of intra-observer variation in prostate volume measurement on prostate-specific antigen density calculations among prostate cancer active surveillance participantsJoan S Ko, Patricia Landis, H Ballentine Carter, et al.
The Journal of Urology|December 11, 2003
An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy seriesMisop Han, Alan W Partin, David Y Chan, et al.
Urology|January 30, 2004
Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancerGlenn M Cannon, Patrick C Walsh, Alan W Partin, et al.
The Journal of Applied Laboratory Medicine|February 27, 2021
High "phi"veLori J Sokoll, Leslie Mangold, Phaedre Mohr, et al.
Urology|October 18, 2002
Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancerRobert W Veltri, M Craig Miller, Gerard J O'dowd, et al.
Pageof 35